Relationship of Nm23 to Proteolytic Factors, Proliferation and Motility in Breast Cancer Tissues and Cell Lines

Overview

Journal Br J Cancer

Specialty Oncology

Date 1998 Sep 22

PMID 9743288

Citations 27

Authors

R L Russell

A N Pedersen

J Kantor

K Geisinger

R Long

N Zbieranski

A Townsend

B Shelton

N Brunner

T E Kute

Affiliations

Soon will be listed here.

Abstract

Low expression of the antimetastatic gene nm23 has been associated with shorter overall survival in breast cancer. To better understand the mechanism(s) of action of this protein, we compared the levels of the nm23 protein in 152 breast cancer samples with other factors known to be involved in metastasis or related to prognosis. There was no significant relationship between either of the nm23 isoforms and cathepsin D (Cat-D), urokinase plasminogen activator (uPA), its inhibitor (PAI-1), steroid hormone receptors or ploidy status. A marginal inverse correlation was observed between per cent S-phase and nm23-H1 expression (r = -0.193, P = 0.047) and a positive correlation was observed between uPA receptor (uPAR) and both nm23-H1 (r = 0.263, P = 0.0018) and nm23-H2 (r = 0.230, P = 0.0064). The nm23-H1 gene was transfected into MDA-MB-231 human breast cancer cells and 12 clones were selected, of which two were characterized extensively. We found no significant differences in Cat-D, uPA, PAI-1 or uPAR, as a function of nm23 expression in either the MDA-MB-231 cells or the transfected clones. Compared with the parent cell line, we did observe a dose-dependent decrease in growth factor-stimulated motility and a decrease in metastatic potential in two clones with four- and eightfold elevated nm23-H1 expression, whereas the proliferative activities were similar. We conclude that the decreased metastatic potential might be related to down-regulation of growth factor-stimulated motility.

Citing Articles

Cellular senescence and metabolic reprogramming model based on bulk/single-cell RNA sequencing reveals PTGER4 as a therapeutic target for ccRCC.

Zhou L, Zeng Y, Liu Y, Du K, Luo Y, Dai Y BMC Cancer. 2024; 24(1):451.

PMID: 38605343 PMC: 11007942. DOI: 10.1186/s12885-024-12234-5.

Whole-genome sequencing analysis of semi-supercentenarians.

Garagnani P, Marquis J, Delledonne M, Pirazzini C, Marasco E, Kwiatkowska K Elife. 2021; 10.

PMID: 33941312 PMC: 8096429. DOI: 10.7554/eLife.57849.

Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer.

Jahanban-Esfahlan R, Seidi K, Manjili M, Jahanban-Esfahlan A, Javaheri T, Zare P Cancers (Basel). 2019; 11(8).

PMID: 31430951 PMC: 6721805. DOI: 10.3390/cancers11081207.

The relationship of NM23 (NME) metastasis suppressor histidine phosphorylation to its nucleoside diphosphate kinase, histidine protein kinase and motility suppression activities.

Khan I, Steeg P Oncotarget. 2018; 9(12):10185-10202.

PMID: 29535799 PMC: 5828198. DOI: 10.18632/oncotarget.23796.

Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis.

Nishida-Aoki N, Tominaga N, Takeshita F, Sonoda H, Yoshioka Y, Ochiya T Mol Ther. 2017; 25(1):181-191.

PMID: 28129113 PMC: 5363297. DOI: 10.1016/j.ymthe.2016.10.009.

References

Liotta L, Steeg P, Stetler-Stevenson W . Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64(2):327-36. DOI: 10.1016/0092-8674(91)90642-c. View

Stahl J, Leone A, Rosengard A, Porter L, King C, Steeg P . Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991; 51(1):445-9. View

Leone A, Flatow U, King C, Sandeen M, Margulies I, Liotta L . Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell. 1991; 65(1):25-35. DOI: 10.1016/0092-8674(91)90404-m. View

Gilles A, Presecan E, Vonica A, Lascu I . Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem. 1991; 266(14):8784-9. View

BARNES R, Masood S, Barker E, Rosengard A, Coggin D, Crowell T . Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol. 1991; 139(2):245-50. PMC: 1886087. View

Campbell P, NOVAK J, Yanosick T, McMaster J . Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology. 1992; 130(3):1401-12. DOI: 10.1210/endo.130.3.1371448. View

Sastre-Garau X, Lacombe M, Jouve M, Veron M, Magdelenat H . Nucleoside diphosphate kinase/NM23 expression in breast cancer: lack of correlation with lymph-node metastasis. Int J Cancer. 1992; 50(4):533-8. DOI: 10.1002/ijc.2910500406. View

Stracke M, Liotta L . Multi-step cascade of tumor cell metastasis. In Vivo. 1992; 6(4):309-16. View

Kute T, Shao Z, Sugg N, Long R, Russell G, Case L . Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res. 1992; 52(19):5198-203. View

10.

Brunner N, Thompson E, Spang-Thomsen M, Rygaard J, Dano K, Zwiebel J . lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer. 1992; 28A(12):1989-95. DOI: 10.1016/0959-8049(92)90245-w. View

11.

OSSOWSKI L . Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992; 52(24):6754-60. View

12.

Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H . Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993; 24(3):195-208. DOI: 10.1007/BF01833260. View

13.

Royds J, Stephenson T, Rees R, Shorthouse A, Silcocks P . Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst. 1993; 85(9):727-31. DOI: 10.1093/jnci/85.9.727. View

14.

Kantor J, McCormick B, Steeg P, Zetter B . Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res. 1993; 53(9):1971-3. View

15.

Christensen I, Rosenquist C, Brunner N, Mouridsen H, Dano K, Blichert-Toft M . High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53(11):2513-21. View

16.

Leone A, Flatow U, Vanhoutte K, Steeg P . Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene. 1993; 8(9):2325-33. View

17.

Rosenquist C, Thorpe S, Dano K . Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat. 1993; 28(3):223-9. DOI: 10.1007/BF00666583. View

18.

Sawan A, Lascu I, Veron M, Anderson J, Wright C, Horne C . NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J Pathol. 1994; 172(1):27-34. DOI: 10.1002/path.1711720107. View

19.

Howlett A, Petersen O, Steeg P, Bissell M . A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst. 1994; 86(24):1838-44. PMC: 3004774. DOI: 10.1093/jnci/86.24.1838. View

20.

Goodall R, Dawkins H, Robbins P, Hahnel E, Sarna M, Hahnel R . Evaluation of the expression levels of nm23-H1 mRNA in primary breast cancer, benign breast disease, axillary lymph nodes and normal breast tissue. Pathology. 1994; 26(4):423-8. DOI: 10.1080/00313029400169122. View